Professor Tobias Arkenau

Professor Tobias Arkenau is a seasoned expert in oncology drug development, currently serving as Chief Medical Officer and Global Head of Drug Development at Ellipses Pharma since May 2022. Prior to this role, Arkenau held prominent positions including Clinical Lead Oncology Service Line at HCA International Ltd and Executive Medical Director at Sarah Cannon Research Institute UK, where the focus was on drug development for gastrointestinal cancers and melanoma. With a strong academic background as a Professor at UCL and experience as a Team Leader in Clinical Drug Development at the University of New South Wales, Arkenau's clinical research expertise was further enhanced as a Senior Clinical Research Fellow at the Royal Marsden Hospital. Early career experience includes roles in internal medicine and oncology at Hospital Bremen East. Arkenau holds MD and PhD degrees in medicine from Medical School Hanover and Martin Luther University Halle.